^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABP 206 (nivolumab biosimilar)
i
Other names: ABP 206, ABP-206, ABP206
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amgen
Drug class:
PD1 inhibitor
Related drugs:
7d
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy (clinicaltrials.gov)
P2, N=20, Not yet recruiting, Emory University
New P2 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • ABP 206 (nivolumab biosimilar)
16d
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
P2/3, N=76, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3)
|
Opdivo (nivolumab) • cytarabine • azacitidine • Rydapt (midostaurin) • decitabine • ABP 206 (nivolumab biosimilar) • Starasid (cytarabine ocfosfate)
22d
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma (clinicaltrials.gov)
P3, N=256, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
23d
DIAL: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (clinicaltrials.gov)
P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
Trial completion date • Combination therapy • Tumor mutational burden • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD27 (CD27 Molecule) • IRF4 (Interferon regulatory factor 4)
|
BCL6 rearrangement • BCL2 rearrangement
|
Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar)
1m
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (clinicaltrials.gov)
P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | N=40 --> 15 | Trial completion date: Sep 2027 --> Nov 2025 | Trial primary completion date: Sep 2027 --> Sep 2024
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • CD14 (CD14 Molecule) • CD24 (CD24 Molecule) • ITGAM (Integrin, alpha M) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • PD-1 expression • TFEB translocation
|
Opdivo (nivolumab) • Inlyta (axitinib) • ABP 206 (nivolumab biosimilar)
1m
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
1m
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial (clinicaltrials.gov)
P2, N=82, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> May 2024
Trial completion date • Trial primary completion date • Minimal residual disease
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
1m
DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov)
P3, N=300, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Metastases
|
BRAF mutation • BRAF V600
|
THXID® BRAF Kit • cobas® 4800 BRAF V600 Mutation Test
|
Opdivo (nivolumab) • Mekinist (trametinib) • Yervoy (ipilimumab) • Tafinlar (dabrafenib) • ABP 206 (nivolumab biosimilar)
2ms
AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
P2, N=300, Suspended, National Cancer Institute (NCI) | N=550 --> 300
Enrollment change • Combination therapy • Checkpoint inhibition
|
CD19 (CD19 Molecule)
|
CD19 expression
|
Opdivo (nivolumab) • cytarabine • Blincyto (blinatumomab) • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Hemady (dexamethasone tablets) • ABP 206 (nivolumab biosimilar) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase) • Starasid (cytarabine ocfosfate) • dexamethasone injection
2ms
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (clinicaltrials.gov)
P3, N=1175, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)
2ms
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov)
P1, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025
Trial completion date • Checkpoint inhibition • Checkpoint block • Metastases
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
BRAF mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • prednisone • ABP 206 (nivolumab biosimilar)
2ms
NCI-2016-01300: Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=28, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Jul 2025
Trial completion date • Combination therapy • Checkpoint inhibition • IO biomarker
|
CD19 (CD19 Molecule) • CD34 (CD34 molecule) • MME (Membrane Metalloendopeptidase)
|
CD19 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Blincyto (blinatumomab) • ABP 206 (nivolumab biosimilar)
2ms
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
P2, N=66, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
Enrollment open • Tumor mutational burden • IO biomarker • Metastases
|
TMB (Tumor Mutational Burden) • CD68 (CD68 Molecule)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)
2ms
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma (clinicaltrials.gov)
P3, N=249, Recruiting, Amgen | Trial completion date: Jul 2025 --> Nov 2025 | Trial primary completion date: Jul 2025 --> Nov 2025
Trial completion date • Trial primary completion date • Metastases
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
2ms
S14-00011: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=146, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
Enrollment closed
|
PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • LGALS1 (Galectin 1) • ICOS (Inducible T Cell Costimulator)
|
TNFRSF8 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • ABP 206 (nivolumab biosimilar)
2ms
S2107: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (clinicaltrials.gov)
P2, N=84, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Feb 2026 | Trial primary completion date: Aug 2024 --> Feb 2026
Trial completion date • Trial primary completion date • Metastases
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
BRAF V600E • BRAF V600
|
Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)
3ms
S2107: Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (clinicaltrials.gov)
P2, N=86, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Oct 2025
Enrollment closed • Trial completion date
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
BRAF V600E • BRAF V600
|
Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)
3ms
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients (clinicaltrials.gov)
P3, N=205, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed • Checkpoint inhibition • Metastases
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • carboplatin • paclitaxel • ABP 206 (nivolumab biosimilar)
3ms
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
P1, N=95, Terminated, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Aug 2024 | Active, not recruiting --> Terminated; Inadequate accrual rate
Trial completion date • Trial termination
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
3ms
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
P1, N=95, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Aug 2024 --> May 2024
Enrollment closed • Trial completion date • Trial primary completion date • Surgery • Metastases
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
3ms
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
3ms
NRG-GY025: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (clinicaltrials.gov)
P2, N=90, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
Enrollment open • Mismatch repair
|
MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
3ms
ETCTN-9844: Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov)
P1, N=57, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Sep 2025
Trial completion date • IO biomarker • Surgery • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CD86 (CD86 Molecule)
|
HR positive • HER-2 negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Jingzhuda (entinostat) • ABP 206 (nivolumab biosimilar)
4ms
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (clinicaltrials.gov)
P1/2, N=16, Recruiting, National Cancer Institute (NCI) | Phase classification: P2 --> P1/2
Phase classification • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • sirolimus • ABP 206 (nivolumab biosimilar)
4ms
AIM-NIVO: Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (clinicaltrials.gov)
P1, N=300, Recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2026
Trial completion date • Trial primary completion date • Metastases
|
MSI (Microsatellite instability) • IL2 (Interleukin 2)
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
4ms
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=50, Recruiting, Emory University | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • IO biomarker • Metastases
|
Opdivo (nivolumab) • avutometinib (VS-6766) • defactinib (VS-6063) • ABP 206 (nivolumab biosimilar)
4ms
NRG-GY025: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (clinicaltrials.gov)
P2, N=90, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
Trial suspension • Mismatch repair
|
MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
5ms
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (clinicaltrials.gov)
P3, N=636, Suspended, National Cancer Institute (NCI) | Active, not recruiting --> Suspended
Trial suspension • Tumor mutational burden • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • cisplatin • ABP 206 (nivolumab biosimilar)
5ms
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (clinicaltrials.gov)
P3, N=636, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed • Tumor mutational burden • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • cisplatin • ABP 206 (nivolumab biosimilar)
5ms
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (clinicaltrials.gov)
P2, N=16, Recruiting, National Cancer Institute (NCI) | Phase classification: P1/2 --> P2
Phase classification • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • sirolimus • ABP 206 (nivolumab biosimilar)
5ms
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2033 --> May 2026 | Trial primary completion date: May 2033 --> May 2026
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
5ms
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2033 | Trial primary completion date: May 2026 --> May 2033
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
5ms
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=50, Not yet recruiting, Emory University
New P2 trial • Combination therapy • IO biomarker • Metastases
|
Opdivo (nivolumab) • avutometinib (VS-6766) • defactinib (VS-6063) • ABP 206 (nivolumab biosimilar)
6ms
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov)
P2, N=314, Recruiting, National Cancer Institute (NCI) | N=224 --> 314
Enrollment change
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
6ms
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (clinicaltrials.gov)
P2, N=68, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Sep 2025
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
|
Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar)
7ms
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=1, Active, not recruiting, National Cancer Institute (NCI) | N=13 --> 1 | Trial completion date: Feb 2025 --> Jun 2025
Enrollment change • Trial completion date • Combination therapy • Tumor mutational burden
|
TP53 (Tumor protein P53)
|
Opdivo (nivolumab) • Venclexta (venetoclax) • decitabine • ABP 206 (nivolumab biosimilar)
7ms
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov)
P3, N=244, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Sep 2027 | Trial primary completion date: Dec 2028 --> Sep 2027
Trial completion date • Trial primary completion date • Combination therapy
|
Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • prednisolone
7ms
PARAMMUNE: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (clinicaltrials.gov)
P2/3, N=224, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Opdivo (nivolumab) • paclitaxel • Cyramza (ramucirumab) • ABP 206 (nivolumab biosimilar)
7ms
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study (clinicaltrials.gov)
P2/3; Phase classification: P3 --> P2/3
Phase classification
|
Signatera™
|
Opdivo (nivolumab) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)
7ms
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (clinicaltrials.gov)
P3, N=1175, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)
7ms
A Study Using a New Drug, Nivolumab, in Combination With Chemotherapy Drugs to Treat a Type of Cancer Called Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov)
P2, N=50, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Jan 2025
Enrollment open • Trial initiation date • Combination therapy
|
Opdivo (nivolumab) • cisplatin • gemcitabine • ABP 206 (nivolumab biosimilar)
7ms
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial (clinicaltrials.gov)
P2/3, N=224, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2024 --> Jan 2025
Trial initiation date • Metastases
|
Opdivo (nivolumab) • paclitaxel • Cyramza (ramucirumab) • ABP 206 (nivolumab biosimilar)
Share via
